Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

QN-019a

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Qihan Biotech

Drug class:

CD19 inhibitor, NK cell stimulant

Related drugs:

‹

Super NK cell therapy (0)

TROP2-CAR-NK (0)

UD TGFbetai NK cells (0)

m-ceNK cells (0)

blinatumomab (52)

tafasitamab-cxix (3)

BTN2A1/3A1-Fc-CD19scFv (0)

CAR-NK-CD19 cells (0)

CB CAR-NK019 (0)

CD19.t-haNK (0)

Imtox19/Imtox22 (0)

inebilizumab-cdon (0)

anti CD19/CD22 CAR NK cells (0)

autologous TRAC locus-inserted CD19-STAR-T (0)

dualCAR-NK19/70 (0)

universal chimeric antigen receptor-modified AT19 cells (0)

pomalidomide (16)

AFM13/AB-101 (1)

cytotoxic lymphocyte-based cancer vaccine (0)

CAR-ITNK cells (0)

CAR.70/IL15-transduced CB-NK cells (0)

CD123 targeted CAR-NK (0)

CD33/CLL1 dual CAR-NK cell (0)

CDH17 CAR-NK cell therapy (0)

CLDN6-CAR-NK cell therapy (0)

CYTO NK-102 (0)

DC vaccine for prostate cancer (0)

primed NK cell therapy (0)

Magicell-NK (0)

NK/γδ T cell-enriched cell therapy (0)

NK92-CD16-158V (0)

NKG2D CAR-NK cell therapy (0)

NKG2D-CAR-NK92 cells (0)

Super NK cell therapy (0)

TROP2-CAR-NK (0)

UD TGFbetai NK cells (0)

m-ceNK cells (0)

›

over2years

Natural Killer (NK) Cell Therapy for B-Cell Malignancies (clinicaltrials.gov)

P1, N=24, Recruiting, Zhejiang University

over 2 years ago

New P1 trial • Combination therapy

|

CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)

|

CD20 expression • CD19 expression

|

Rituxan (rituximab) • fludarabine IV • QN-019a